Emerging Infectious Disease ISSN: 1080-6059

Reproducibility of Serologic Assays for Influenza Virus A (H5N1)

Iain Stephenson

, Alan Heath, Diane Major, Robert W. Newman, Katja Hoschler, Wang Junzi, Jacqueline M. Katz, Jerry P. Weir, Maria C. Zambon, and John M. Wood

Author affiliations: University of Leicester, Leicester, UK (I. Stephenson); National Institute for Biological Standards and Controls, Potters Bar, UK (A. Heath, D. Major, R.W. Newman, J.M. Wood); Health Protection Agency, Colindale, UK (K. Hoschler, M.C. Zambon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.M. Katz); Food and Drug Administration, Rockville, Maryland, USA (J.P. Weir); National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People’s Republic of China (W. Junzhi)

Main Article

Figure 1

Intralaboratory reproducibility showing proportion (%) of replicate assays differing by >2-fold (A, B) and >4-fold (C, D) by horse hemagglutination-inhibition and neutralization assays for each participating laboratory for all serum samples (A, C) and postvaccination serum samples (B, D). Laboratory 11 did not return hemagglutinin-inhibition result.

Figure 1. Intralaboratory reproducibility showing proportion (%) of replicate assays differing by >2-fold (A, B) and >4-fold (C, D) by horse hemagglutination-inhibition and neutralization assays for each participating laboratory for all serum samples (A, C) and postvaccination serum samples (B, D). Laboratory 11 did not return hemagglutinin-inhibition result.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.